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a b s t r a c t
This article provides an overview of present knowledge regarding the relationship between the choliner-
gic systemand sigma-1 receptors, anddiscusses potential applications of sigma-1 receptor agonists in the
treatment ofmemorydeﬁcits and cognitive disorders. Sigma-1 receptors, initially considered as a subtype
of the opioid family, are unique ligand-regulated molecular chaperones in the endoplasmatic reticulum
playing amodulatory role in intracellular calciumsignaling and in the activity of several neurotransmitter
systems, particularly the cholinergic and glutamatergic pathways. Several central nervous system (CNS)
drugs show high to moderate afﬁnities for sigma-1 receptors, including acetylcholinesterase inhibitors
(donepezil), antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (ﬂuvoxam-




functions both via their primary targets and by activating sigma-1 receptors in the CNS. Sigma-1 agonists
show powerful anti-amnesic and neuroprotective effects in a large variety of animal models of cogni-
tive dysfunction involving, among others (i) pharmacologic target blockade (with muscarinic or NMDA
receptor antagonists or p-chloroamphetamine); (ii) selective lesioning of cholinergic neurons; (iii) CNS
administration of -amyloid peptides; (iv) aging-induced memory loss, both in normal and senescent-
accelerated rodents; (v) neurodegeneration induced by toxic compounds (CO, trimethyltin, cocaine), and
(vi) prenatal restraint stress.
© 2010 Elsevier B.V. All rights reserved.
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Fig. 1. Two schemes illustrating the hypothetical function of sigma-1 receptors.
Above: Under baseline (resting) conditions, sigma-1 receptors (black oval) largely
reside at the endoplasmatic reticulum (ER), in association with ankyrin (green oval)
and IP3 receptors (red bar). After agonist stimulation, sigma-1 receptors translocate
to the plasmalemma where they can regulate ion channels (K+ or NMDA-receptor
associated Ca2+), probably by direct protein–protein interactions. Below: Sigma-1
receptor agonists induce dissociation and translocation of sigma-1 receptors plus
ankyrin from the sigma-1 receptor–ankyrin-IP3 receptor complex. As a result, both
the binding of IP3 to its receptor and Ca2+ efﬂux from the ER are increased. Sigma-1
antagonists inducedissociationof only sigma-1 receptors fromthe complex, ankyrin
remaining in place. Antagonists donot affect Ca2+ releasewhen given alone, but they44 A. van Waarde et al. / Behaviour
. Introduction
Cholinergic neurotransmission is a crucial process underlying
emory and cognitive function. Cholinergic basal forebrain neu-
ons in the nucleus basalis magnocellularis innervate the cerebral
ortex, amygdaloid complex, or hippocampus and are essential
or learning and memory formation [1,28]. Some cortical cholin-
rgic activity is lost in normal aging. Patients suffering from AD
r related dementias display a severe degeneration of cholinergic
eurons and a corresponding loss of cortical cholinergic neuro-
ransmission, which is one of the factors underlying their memory
eﬁcits [4,18,19]. Administrationof an anticholinergic drug, such as
hemuscarinic antagonist scopolamine, to experimental animals or
ealthyvolunteers results in striking impairments ofmemory func-
ionwhich resemble Alzheimer dementia [131]. On the other hand,
cetylcholinesterase (AChE) inhibitors such as tacrine, physostig-
ine, rivastigmine and galantamine which suppress breakdown
f the neurotransmitter acetylcholine, can temporarily improve
emory function in somedemented patients and in animalmodels
f amnesia [64].
The sigma-1 receptor, a unique orphan receptor, is strongly
xpressed in neurons and in glia [35,37]. Neurosteroids, i.e.
teroid hormones which are synthesized within the brain itself
84,95,101,143], and sphingolipids [134] interact with sigma-1
ites which are now considered as ligand-regulated molecu-
ar chaperones modulating the activity of voltage-regulated and
igand-gated ion channels [98], intracellular calcium signaling [39],
nd the release of various neurotransmitters including acetyl-
holine [45,58,63] and glutamate [107]. Occupancy of sigma-1
eceptors by agonists causes translocation of the receptor protein
rom the endoplasmatic reticulum to the cell membranewhere the
eceptor can regulate ion channels and neurotransmitter release
36,39] (Fig. 1). The sigma-1 receptor is implicated in cellular
ifferentiation [37,40], neuroplasticity [145,149], neuroprotection
71,89], and cognitive functioning of the brain [85].
As both the cholinergic system and sigma-1 receptors are
mplied in cognition, we will in this article present an overview
f current knowledge regarding the relationship between these
euronal pathways, and discuss potential applications of sigma-1
eceptor agonists in the treatment ofmemorydeﬁcits and cognitive
isorders.
. Acetylcholine and sigma-1 receptor function
Sigma-1 receptor agonists are potent modulators of acetyl-
holine release, both in vitro and in vivo. Igmesine and (+)SKF
0,047 potentiate the KCl-evoked release of 3H-acetylcholine from
at hippocampal slices, and this effect can be blocked by the sigma
ntagonist haloperidol [58]. The sigma-1 receptor agonist SA4503
ose-dependently increases the electrically evoked release of 3H-
cetylcholine fromhippocampal butnot striatal slices isolated from
at brain [45].
Using in vivo microdialysis in freely moving rats, extracellular
cetylcholine levels in the frontal cortex were found to be acutely
nddose-dependently increaseduponadministrationof the sigma-
receptor agonists (+)-SKF 10,047, (+)-3-PPP, (±)-pentazocine and
TG. The effect of SKF 10,047 was stereoselective and it could
e reversed by the sigma antagonist haloperidol [75,76]. In later
xperiments, (+)-SKF 10,047 was shown to also increase extracel-
ular acetylcholine in the hippocampus in a stereoselective fashion
nd this effect could also be blocked by haloperidol [77]. Regional
ifferences in the stimulation of acetylcholine release by sigma-
receptor agonists were subsequently observed. (+)-SKF 10,047
nd DTG increased the release of acetylcholine in hippocampus
nd frontal cortex, but in the rat striatum, DTG had no and (+)-
KF 10,047 had only a marginal effect [62]. Acetylcholine releaseimpede the potentiation of Ca2+ efﬂux by sigma-1 receptor agonists. After [13,40].
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of the article.)
in the hippocampus and frontal cortex was also strongly increased
by the sigma-1 agonist SA4503, whereas acetylcholine release in
the striatum was not affected [63,79] (see Fig. 2). The absence of
an increase of striatal acetylcholine levels after administration of
sigma-1 receptor agonists may be the reason why such drugs do
not display some undesired side effects which are frequently seen
after administration of acetylcholinesterase (AChE) inhibitors [63].
Since selective sigma-1 receptor agonists can facilitate the activ-
ity of cholinergic systems by stimulating acetylcholine release,
particularly in the cortex and hippocampus, such drugs have the
potential to ameliorate the memory impairments resulting from
cholinergic dysfunction.
However, the capability of sigma-1 receptor agonists to amelio-
rate such impairments appears to be not solely due to modulation
of residual acetylcholine release. In a recent study involving the
potent and selective sigma-1 agonist (±)-PPCC (Ki at muscarinic
receptors >10,000nM) and cholinergic lesions of varying severity,
itwasnoted that the anti-amnesic effects of the sigma receptor ago-
A. van Waarde et al. / Behavioural Brai
Fig. 2. Upper panel: The sigma-1 receptor agonist SA4503 (10mg/kg, per os, admin-









an amino acid substitution Q2P) in the ﬁrst exon [151]. The hap-
F
dut not in the striatum of freely moving rats. Lower panel: The effect of SA4503 on
cetylcholine release is counteracted by the sigma-1 receptor antagonist NE-100
0.5mg/kg, co-administered with SA4503). After [63,79].
ist occur even in animals with complete cholinergic depletion, i.e.
total absence of cholinergic neurons in the basal forebrain nuclei
2]. Pretreatment of animals with the sigma-1 receptor antago-
ist BD1047 blocked the anti-amnesic effects of (±)-PPCC [2]. Thus,
PCC appears to improve cognition through sigma-1 receptors via
ig. 3. Age-related increases of sigma-1 receptor density in rhesus monkey brain (upper
opamine D2/D3 receptor numbers with aging in human brain. Data from [60], [122], [14n Research 221 (2011) 543–554 545
additional, mechanisms than stimulation of acetylcholine release.
Some possiblemechanisms are discussed in subsequent sections of
this paper.
3. Changes of sigma receptor density in aging and
neurodegenerative disease
Whensigma-1 receptordensity in thebrainof aged (20–28years
old) and young adult (4–8 years old) monkeys was compared using
the radioligand 11C-SA4503 and PET, a highly signiﬁcant increase
(160–210%) of the binding potential (BP) was observed in aged ani-
mals [60]. In a similar PET study in humans, 11C-SA4503 binding
was found to be unchanged in the human brain during healthy
aging [47]. This contrasts strikingly with the age-dependent loss
of cholinergic, glutamatergic and dopaminergic receptors which
occurs in primates (Fig. 3).
Using autoradiography and the non-subtype-selective sigma
ligand 3H-DTG, a signiﬁcant, 26% loss of binding sites was noted
in the CA1 stratum pyramidale region of the hippocampus of
Alzheimer’s disease (AD) patients as compared to healthy controls.
This loss of sigma receptors correlatedwith a 29% loss of pyramidal
cells [56]. These preliminary results suggested that sigma receptors
are preferentially located on pyramidal cells in the CA1 region of
the hippocampus.
In later PET studies, a loss of sigma-1 receptors from the brain of
patients with AD was indeed observed [109]. The BP of the sigma-
1 ligand 11C-SA4503 was signiﬁcantly reduced (by 44–60%) in the
frontal, temporal, and occipital lobe, cerebellum and thalamus of
early AD patients as compared to healthy controls, but not in the
hippocampus [109].
Two genetic variants of the sigma-1 receptor gene could
affect the susceptibility of humans to AD, i.e. G-241T/C-240T (rs.
1799729) in the proximal promoter region and A61C (resulting inlotype TT-C has been suggested to provide protection against AD.
However, in a later study in a group of Polish patients (219 subjects
with late-onset AD, 97 subjects with mild cognitive impairment
and 308 nondemented subjects), no signiﬁcant differences for the
left) compared to the decreases of muscarinic M1/M4, serotonin-2A (5-HT2A), and
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igma-1 receptor allele, genotype, haplotype, and diplotype distri-
utions were observed between the studied groups [73].
In a small groupof patientswith early Parkinson’s disease (n=6),
he BP of 11C-SA4503 was found to be signiﬁcantly lower on the
ore affected than the less affected side of the anterior putamen,
lthough therewas no signiﬁcant difference in BP betweenpatients
nd controls [108]. These data suggest that Parkinson’s diseasemay
e associated with a loss of sigma-1 receptors from the putamen,
lthough the decrease is less striking than that observed in the
erebral cortex in AD.
In the rodent brain, sigma-1 receptor density was generally
ound to be preserved during aging. In a recent study involving
ealthy controls and senescent-accelerated mice (SAM), no dif-
erences between 6-, 9- and 12-month-old rodents regarding the
igma-1 receptor density of various brain regions were observed,
either at the level of mRNA nor at the protein level (histochem-
stry, binding of 3H-(+)-SKF 10,047). However, in aged (12-month)
AM, the antidepressant efﬁcacy of the sigma-1 agonist igme-
ine was increased. This augmented response may be due to
ecreased levels of neurosteroids in these animals, particularlypro-
esterone, a steroid with sigma-1 receptor antagonist action [132].
he efﬁcacy of sigma-1 receptor agonists is known to be inversely
orrelated to brain progesterone levels. In rats treatedwith chronic
ntracerebroventricular infusion of -amyloid(1–40) protein, or in
-amyloid(25–35) peptide-treated mice, a signiﬁcant decrease of
erebral progesterone levels is accompanied by a corresponding
ncrease of the antidepressant activity of sigma-1 receptor ago-
ists [154,155]. In another study onmurine aging, no differences in
erebral sigma-1 receptor density were observed between 2- and
4-month-oldC57/BL6mice, neither at themRNAnorat theprotein
evel [133].
Changes of sigma-1 and sigma-2 receptors in aging rat brain
ave been examined as well, by applying the radioligands 3H-
A4503, 3H-(+)-pentazocine and 3H-DTG for binding studies in
rain homogenates of 1.5-, 6-, 12- and 24-month-old Fisher-344
ats. The number of binding sites increased with aging, but the
inding afﬁnity of all ligands was decreased. Apparently, increases
f receptor density (over)compensate for a reduced afﬁnity of the
eceptor proteins to agonists in this rodent strain, and as a con-
equence, ligand binding is increased at old age [51], particularly
t ages greater than 12 months. In an older study which used 3H-
aloperidol (in combination with 50nM unlabeled spiperone) to
uantify sigma-1 plus sigma-2 receptors, receptor density in the
rain of Fisher-344 rats was found to be unaltered between post-
atal day 1 and age 12 months [69].
These ﬁndings of a preserved receptor density may perhaps not
e generalized to all rat strains, sincemiddle-agedSprague–Dawley
ats (5–6 months old) were reported to have fewer sigma bind-
ng sites and sites with lower afﬁnity for 3H-DTG than young
dult animals (2–3 months old). The older animals also exhibited
decreased behavioral response to sigma ligands injected into the
ubstantia nigra [74]. Another research group which used 3H-(+)-
PP conﬁrmed that the binding sites for this ligand in the brain of
prague–Dawley rats are present at high density during the peri-
atal period, and decline thereafter [129].
. Sigma ligands improve cognition in animal models of
ognitive impairment
Sigma-1 agonists (applied systemically) have shown anti-
mnesic efﬁcacy in several animalmodels of cognitive impairment.
oth pharmacological and pathological models of amnesia have
een examined (see Table 1 for an overview). These include: (i)
holinergic deﬁcits (either induced by muscarinic antagonists or
y lesions of the forebrain or the nucleus basalis resulting in a
elective loss of cholinergic neurons); (ii) pathology induced byn Research 221 (2011) 543–554
direct administration of -amyloid(25–35) peptide to the rodent
CNS, an animal model of Alzheimer’s disease; (iii) aging-induced
losses of memory function, both in normal mice and SAM; (iv)
neurodegeneration caused by exposure of animals to CO gas, or to
trimethyltin; (v) prenatal stress (restraint, or exposure to cocaine),
and (vi) glutamatergic, serotonergic, or calcium channel deﬁcits
induced by various drugs. The beneﬁcial effects of sigma-1 receptor
agonists on cognitive performancewere detected inmany different
cognitive tests assessing short-term (workingmemory), long-term
(reference memory), contextual or spatial memory processes.
For example, the sigma-1 receptor agonists (+)-SKF 10,047,
pentazocine, DTG, (+)-3-PPP, igmesine and SA4503 prevented the
scopolamine-induced amnesia of mice and rats in passive avoid-
ance tasks, and the beneﬁcial action of these compounds was
blocked by sigma-1 receptor antagonists like NE-100. The anti-
amnesic effects of SA4503 were blocked after sigma-1 receptor
antisense administration, but not after administration of a mis-
match oligodeoxynucleotide [79,80,81,93,139]. Thus, activation of
the sigma-1 receptor is involved in the improvement of cognition,
and sigma-1 agonists have potential for the treatment of amnesia
resulting from cholinergic dysfunction.
Sigma-1 receptor agonists such as (+)-SKF 10,047, (+)-
pentazocine, DTG, PRE084 and SA4503 also showed a potent
anti-amnesic action against the cognitive deﬁcits induced by
NMDA-receptorblockade inmiceand rats, e.g. treatmentof animals
with the non-competitive NMDA receptor antagonist dizocilpine
before the learning test. These beneﬁcial effects were stereoselec-
tive and were blocked by pretreatment of animals with sigma-1
antagonists such as BMY14802, haloperidol or NE-100 (see Table 1
for references).
Neurotoxicitymodels of cognitive impairmentwhich have been
employed for testing cognitive enhancement by sigma-1 recep-
tor agonists include repeated exposure of mice to CO gas and
trimethyltin administration to rats. The former model results
after 5–7 days in neuronal death that remains restricted to the
CA1 area of the hippocampus [118]. Trimethyltin administration
results in damage of selective neural populations from limbic
structures of the brain [10,11]. In such neurotoxicity models, sim-
ilar ﬁndings were obtained as in the pharmacological models of
amnesia, i.e. sigma-1 receptor agonists improved cognitive per-
formance and this improvement could be blocked by sigma-1
receptor antagonists. However, in contrast to the scopolamine or
dizocilpine-induced amnesia, cognitive impairments after expo-
sure of animals to CO or trimethyltin were alleviated not only by
sigma-1 agonists but also by sigma-2 receptor agonists.
In most behavioral tests, sigma-1 receptor agonists do not facil-
itate and sigma-1 receptor antagonists do not impede the learning
of healthy control animals. Downregulation of sigma-1 receptor
expression using an in vivo antisense approach also does not
affect the learning ability of healthy mice submitted to a pas-
sive avoidance test [93,94]. However, sigma-1 receptor agonists
improve the performance of pharmacologically or pathologically
lesioned animals in standard learning tests, and this improvement
in lesioned rodents canbeblockedby sigma-1 receptor antagonists.
Neuroactive steroids (such as DHEA-S or pregnenolone sulfate)
have similar effects as non-steroid sigma-1 receptor agonists,
whereas progesterone behaves as a sigma-1 receptor antagonist.
These observations suggest that sigma-1 receptors are not directly
involved in learning or memory, but sigma-1 receptor agonists
can modulate neural processes underlying cognition, particularly
under pathological conditions.However, in some publications pro-mnesic effects of sigma-1
receptor agonists have been reported. For example, the neu-
rosteroids DHEA-S and PREG-S, when given either pre- or
post-training, were found to facilitate retention of a modiﬁed
learning task in mice in a dose-dependent manner with a bell-
A. van Waarde et al. / Behavioural Brain Research 221 (2011) 543–554 547
Table 1
Animal models in which sigma-1 agonists have shown anti-amnesic properties.
Amnesia model Species 1 agonists 1 antagonists Other drugs used Behavioral tests Reference
Cholinergic deﬁcit
Scopolamine Rat Igmesine, (+)-3-PPP,
DTG
None Piracetam Passive avoidance [25]





Scopolamine, ibotenic acid forebrain
lesion
Rat SA4503 Haloperidol, NE-100 None Passive avoidance [141]
Scopolamine Mouse (+)-SKF 10,047 Haloperidol, NE-100 (−)SKF 10,047,
physostigmine
Passive avoidance [139]
Ibotenic acid forebrain lesion Rat SA4503 None None Morris water maze [140]
Scopolamine Mouse DHEA-S, PREG-S Progesterone, NE-100 None Y-maze, water maze [152]
Scopolamine Mouse PRE084, SA4503 Antisense Mismatch antisense Y-maze, passive
avoidance
[93]
Scopolamine Rat OPC-14523 NE-100 None Morris water maze [148]
Nucleus basalis lesion Rat Fluoxetine None None Active avoidance [53]
Scopolamine Mouse (+)-Pentazocine Antisense (−)-Pentazocine Y-maze [43,41]
(+)-SKF 10,047 NE-100 U-50,488H [42]










Rat (±)-PPCC BD1047 None Morris water maze [2]
l-NAME, 7-nitroindazole Mouse (+)-SKF 10,047,
(+)-pentazocine
NE-100 None Y-maze [70]
Amyloid-induced neurodegeneration

























Normal aging Rat PRE084 None None Water maze [82]
Normal aging Rat OPC-14523 NE-100 None Morris water maze [148]
Normal aging Mouse PRE084 None None Morris water maze [133]
Hypoxia-induced neurodegeneration
Repeated CO exposure Mouse (+)-SKF 10,047, DTG BMY14802 None Y-maze, passive
avoidance
[87]
Repeated CO exposure Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance [92]
Repeated CO exposure Mouse DHEA Pregnelone, NE-100 None Y-maze, passive
avoidance
[91]






Trimethyltin Rat Igmesine None None Passive avoidance,
radial arm maze
[124]
Trimethyltin Mouse PRE084, DTG, BD1008 NE-100, haloperidol None Passive avoidance [92]
Prenatal stress








Dizocilpine Mouse (+)-SKF 10,047,
(+)-pentazocine, DTG






Dizocilpine Rat (+)-SKF 10,047 (−)SKF 10,047 Three-panel runway
task
[126]
Dizocilpine Mouse DHEA-S BMY14802, haloperidol Y-maze, passive
avoidance
[88]
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Table 1 (Continued )
Amnesia model Species 1 agonists 1 antagonists Other drugs used Behavioral tests Reference
Dizocilpine Rat (+)-SKF 10,047, SA4503 NE-100 None Radial arm maze [163]
Dizocilpine Rat SA4503, DHEA-S,
PREG-S
Progesterone, NE-100 None Radial arm maze [162]
Dizocilpine Mouse PRE084, SA4503 Antisense Mismatch antisense Y-maze, passive
avoidance
[93]
Dizocilpine Mouse PRE084, DHEA-S,
PREG-S
Antisense Mismatch antisense Y-maze, passive
avoidance
[94]
Phencyclidine, dizocilpine Mouse SA4503,
(+)-pentazocine,
(+)-SKF 10,047
NE-100 d-cycloserine, l-NAME One-trial
water-ﬁnding task
[121]
Dizocilpine Mouse Donepezil, igmesine Antisense, BD1047 Rivastigmine, tacrine Y-maze, passive
avoidance
[90]
Phencyclidine Mouse Fluvoxamine, SA4503,
DHEA-S
NE-100 Paroxetine Novel object
recognition task
[31]











































CDEP Mouse (+)-SKF 10,047, DTG,
(+)-3-PPP
Non
haped dose–response curve. This action of the neurosteroids
ppears to be dependent on their interaction with sigma-1 recep-
ors, since it can be blocked by concurrent administration of the
igma antagonist haloperidol [135]. Long-term potentiation (LTP)
n rat hippocampus, a process thought to be crucial for learning
nd memory, is facilitated after chronic (7 days) administration of
he neurosteroid DHEA-S. This potentiation appears to be based
n alterations in postsynaptic neurons since no changes were
bserved in presynaptic glutamate release. DHEA-S appears to
ct through sigma-1 receptors, since the potentiating effect is
bsent when sigma-1 receptor antagonists (NE-100, haloperidol)
re co-administered with the neurosteroid [12]. Another neuros-
eroid with sigma-1 receptor agonist action, PREG-S, has also been
eported to facilitate LTP in the rodent hippocampus by a mech-
nism involving sigma-1 receptors and L-type calcium channels
136]. The non-sulfated forms of the neurosteroids which lack the
igma-1 receptor agonist action (DHEA and PREG) do not potenti-
te LTP [12,136]. Paired-pulse facilitation in hippocampal neurons
rom adult rats, a short-term increase of the postsynaptic poten-
ial, is also potentiated by PREG-S and this potentiation is abolished
fter co-administration of sigma-1 receptor antagonists [138].
ig. 4. PET scans of the brain of a human volunteer, made with the sigma-1 receptor liga
rug, interval 3h (middle) and 10h (right), respectively. The binding of 11C-SA4503 was
rug. Data from our own group, not previously published.maze
None Passive avoidance [78]
5. Improvement of cognitive function in humans
Fluvoxaminehas been reported tobe effective in improving cog-
nitive impairments in ananimalmodel of schizophrenia, in contrast
to paroxetine [31]. Interestingly, ﬂuvoxamine but not paroxetine
was also found to improve the lack of concentration, poormemory,
slowness of mind, and poor executive function in a patient with
schizophrenia [54]. The afﬁnity of ﬂuvoxamine for sigma-1 recep-
tors is more than 50 times higher than that of paroxetine, although
both compounds are potent selective serotonin reuptake inhibitors
(SSRIs) [119]. High occupancy (up to 60%) of sigma-1 receptors in
the human brain was observed with 11C-SA4503 PET after a single
oral dose of 200mg ﬂuvoxamine [48] (see Fig. 4 for a similar occu-
pancy study). These data suggest that sigma-1 receptor agonists
including SSRIs with sigma-1 receptor agonist action, such as ﬂu-
voxamine, may be candidates for treating cognitive impairments
in schizophrenia.
Compounds which combine acetylcholinesterase (AChE) inhi-
bition with sigma-1 receptor agonism exist as well, e.g. donepezil.
A recent paper reported that therapeutic doses of donepezil result
in considerable sigma-1 receptor occupancy in human brain [49].
nd 11C-SA4503, at baseline (left) and after oral administration of an antipsychotic
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igma-1 receptor agonistsmay have potential for treating AD since
he compounds are not only capable of alleviating cognitive deﬁcits
n animal models of cognitive impairment (see above) but they
an also provide neuroprotection against amyloid toxicity (see [83]
or a review). Evidence for such neuroprotective activity has been
rovided both by in vitro experiments in cultured cortical neu-
ons [71] and by in vivo studies in rodents [105,157]. Recently, it
as found that sigma-1 receptor agonists can powerfully suppress
icroglial activation [29]. Such compounds may therefore attenu-
te the inﬂammatory component in neurodegenerative diseases.
More applications of sigma-1 receptor agonists, e.g. in the treat-
ent of depression, anxiety, psychosis, substance abuse, stroke
nd neuropathic pain are discussed in several recent reviews
13,14,32,40,85,98]. Companies involved in the development of
rugs for such indications include M’s Science, AGY Therapeutics,
tsuka American Pharmaceutical, and Sanoﬁ-Aventis [14].
. Modulation of glutamate release by sigma-1 agonists
Besides the well-known deﬁcits of acetylcholine, the neuro-
ransmitter glutamate can be reduced in AD. Both neurotransmit-
ers are supposed to play vital roles in memory [1]. It is thus of
nterest that sigma ligands are capable of modulating glutamate
elease in various areas of the brain.
The neurosteroid PREGS (which is supposed to act as a sigma-1
eceptoragonist) and thesigma-1 receptoragonist (+)-pentazocine,
ut not the (−)-enantiomers of PREGS and pentazocine, or the inac-
ive steroid isopregnanolone enhance the spontaneous release of
lutamate in cultured hippocampal neurons. The sigma receptor
ntagonists haloperidol and BD1063 and a membrane-permeable
alcium chelator block this effect of PREGS. These results suggest
hat hippocampal glutamate release can be enhanced via activa-
ion of presynaptic sigma-1 receptors and an elevation of the levels
f intracellular Ca2+ [107]. Later studies by another research group
onﬁrmed that the spontaneous release of glutamate is enhanced
y PREGS both in the hippocampus and in prelimbic cortex, but
ot in the striatum. The effect of PREGS in the prelimbic cor-
ex appears to be mediated via alpha-1 adrenergic and sigma-1
eceptors, whereas the effect in the hippocampus is dependent
n sigma-1 receptors only. Intracellular calcium released from the
ndoplasmatic reticulum plays a key role in the enhancement of
lutamate release [24]. DHEA-S, another neurosteroid with sigma-
receptor agonist action, also enhances the spontaneous release
f glutamate in prelimbic cortex and hippocampus. The effect of
his compound in the prelimbic cortex appears to be mediated via
opamineD1 andsigma-1 receptors,whereas that in thehippocam-
us occurs only via sigma-1 receptors [23].
Brain-derived neurotrophic factor (BDNF)-induced glutamate
elease in cultured cortical neurons is potentiated by antidepres-
ants with sigma-1 receptor agonist activity such as ﬂuvoxamine
nd imipramine, and this potentiation is blocked by the sigma-1
eceptor antagonist BD1047. Not only pharmacological activation
ut also overexpression of the sigma-1 receptor enhances BDNF-
nhanced glutamate release. The sigma-1 receptor appears to play
n important role in BDNF signaling leading to the release of glu-
amate, and the enhancement of glutamate release seems to occur
ia the PLC-gamma/IP3/Ca2+ pathway [160].
Thus, sigma ligands represent a strategy for modulating
lutamatergic activity within the mammalian brain, and such
odulation could be an additionalmechanismunderlying the anti-
mnesic action of sigma-1 receptor agonists.. Modulation of the NMDA response by sigma-1 agonists
NMDA receptors mediate the induction of LTP and long-term
epression in various brain areas (i.e. long-lasting improvementsn Research 221 (2011) 543–554 549
and impairmentsof synaptic transmission) [3,15,30,55]. Such forms
of synaptic plasticity are considered as important cellular mecha-
nisms underlying learning and memory [9,68,147].
Pharmacological inhibition of NMDA receptor function, by
administration of NMDA antagonists either directly into the brain
or by systemic administration of compounds which can cross the
blood–brain barrier, results in impaired spatial learning and non-
spatial passive avoidance learning in rodents [16,117,130,156].
Knockout mice lacking the NMDA receptor 1 gene in CA1 pyra-
midal cells of the hippocampus exhibit impaired spatial learning
but unimpaired nonspatial learning [150]. Apparently, NMDA-
dependent strengthening of CA1 synapses is essential for the
acquisition and storage of spatial memory.
Inmany studies, sigma-1 receptor agonistswere shown tomod-
ulate responses induced by NMDA receptor activation in various
brain areas such as the hippocampus and prefrontal cortex. Some
responses are potentiated and others inhibited by sigma-1 receptor
agonists. Sigma-1 receptor antagonists when administered alone
are without any effect, but these compounds block the agonist-
induced modulation.
For example, the electrophysiological response of pyramidal
neurons in the CA3 region of the rat dorsal hippocampus to NMDA
(excitatory activation) is potentiated by sigma-1 receptor ago-
nists such as (+)-pentazocine, DTG, BD737, igmesine, L687,384,
or DHEA and therapeutic drugs with signiﬁcant sigma-1 receptor
agonist afﬁnity (the SSRI sertraline and the monoamine oxidase
inhibitor clorgyline), whereas this potentiation is reversed by
sigma-1 receptor antagonists such as haloperidol, BMY14802, NE-
100, progesterone and testosterone [5,6,8,20,112,113,114]. The
potentiation persists for at least 60min and can be sustained by
prolonged microiontophoretic application of a sigma-1 receptor
agonist, indicating that sigma-1 receptors do not rapidly desen-
sitize [5].
Steroid hormones with antagonist action such as progesterone
and testosterone produce a tonic dampening of the function
of sigma-1 receptors and, consequently, of NMDA-mediated
responses. Pregnancy reduces sigma-1 receptor function in the
brain, since a tenfold higher dose of sigma-1 receptor agonists is
required to potentiate the NMDA response of pyramidal neurons
in pregnant female rats than in non-pregnant control animals [7].
In an electrophysiological study in which animals were unilat-
erally lesioned by local injection of colchicine into the mossy ﬁber
system (an afferent system to CA3 pyramidal neurons), the poten-
tiating effect of (+)-pentazocine on the NMDA response was found
to persist on the lesioned side, but the potentiating effects of DTG
and igmesine were abolished after lesioning [21]. These data were
interpreted as suggesting that the test drugswere actingon twodif-
ferent subtypes of sigma receptors, and that the receptors for DTG
and igmesine are located on the mossy ﬁber terminals, in contrast
to the receptors for (+)-pentazocine [21]. In a later study, the effect
of the sigma-2 subtype-selective ligand siramesine was tested on
the neuronal response to NMDA in the CA3 region of the rat dor-
sal hippocampus. Siramesine was found to potentiate the NMDA
response dose-dependentlywith a bell-shaped curve, but the effect
of siramesine could – in contrast to the effect of sigma-1 receptor
agonists – not be reversed by NE-100, haloperidol or progesterone
[17]. Thus, not only sigma-1 but also sigma-2 receptors appear to
be involved in modulation of the NMDA response.
Bell-shaped dose–response curves are a common ﬁnding in
studies regarding the effect of sigma-1 receptor agonists. At low
doses the NMDA response is potentiated but at higher dose the
potentiation is reversed [5,8,111,112]. For example, the sigma-1
receptor agonist SR 31742A increases NMDA-induced inward cur-
rents of pyramidal cells in slices of rat medial prefrontal cortex at
doses ranging from 10nM to 100nM (EC50 23nM), but at doses
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on of NMDA-receptor-mediated neurotransmission by SR 31742A
ay account for the antipsychotic and cognition-enhancing prop-
rties of the drug, whereas the inhibition of NMDA responses at
igher drug concentrations may account for its neuroprotective
ffect [66].
Recently, a molecular mechanism has been proposed which
ay explain how sigma-1 receptor ligands increase the NMDA
esponse. Calcium ions entering the cells through NMDA-receptor-
elated channels normally activate a potassium current via
mall-conductance calcium-activated K+ channels (SK channels).
his current shunts the NMDA receptor responses. Sigma-1
ubtype-selective receptor agonists prevent SK channel opening,
nd consequently increase the NMDA receptor response [72].
. Modulation of calcium homeostasis
The intracellular localization of sigma-1 receptors (mainly in
ndoplasmatic reticulum, but also in nuclear and plasma mem-
ranes and on mitochondria [52,57,102,133,137]) suggests that
hese binding sites could be involved in the regulation of calcium
obilization.
Indeed, sigma-1 receptor activation has been shown to affect
alcium homeostasis. Sigma-1 receptor agonists increased con-
ractility, beating rate and calcium inﬂux in cultured cardiac
yocytes from neonatal rats [26]. Intracellular levels of inosi-
ol triphosphate in these cells were increased as well [123]. In
G108 (neuroblastoma–glioma) cells, various sigma-1 receptor
gonists enhanced the bradykinin-induced increases in cytosolic
ree calcium with bell-shaped dose–response curves whereas this
ffect could be blocked by a sigma-1 receptor antisense oligonu-
leotide, suggesting that sigma-1 receptor activation facilitates
P3-receptor-mediated Ca2+ signaling [34]. In SH-SY5Y (neurob-
astoma) cells, the sigma-1 receptor agonist (+)-pentazocine and
arious neurosteroids also potentiated the bradykinin-induced
a2+ response, and this potentiation was blocked by the sigma
eceptor antagonists haloperidol and progesterone [44]. By expres-
ion of either complete sigma-1 receptors or the N- or C-terminal
egment of the sigma-1 receptor protein in MCF-7 breast can-
er cells (which normally express few sigma-1 receptors), proof
as obtained that sigma-1 receptor overexpression results in an
nhancement of bradykinin-, vasopressin- or ATP-induced calcium
elease, and that the C-terminal segment of the sigma-1 recep-
or is involved in the interaction with the inositol triphosphate
eceptor–ankyrin-B 220 complex [159].
Experiments in adult guinea pig isolated brainstem prepara-
ions have indicated that sigma-1 receptor activation leads to
ctivation of phospholipase C and the beta-1 and beta-2 isoforms
f protein kinase C [116]. In isolated rat hippocampal neurons,
eceptor activation leads to a potentiation of NMDA-receptor-
ediated increases of free intracellular calcium [115]. However, in
at frontal cortical neurons, sigma receptor ligands were found to
educe the NMDA-induced Ca2+ inﬂux. Sigma-1-subtype-selective
ompounds (igmesine, (+)-pentazocine) particularly affected the
ustained phase of the Ca2+ response to NMDA, whereas non-
ubtype-selective compounds (DTG, haloperidol) reduced the
nitial and sustained phases to the same degree. The inhibition
f the sustained phase was directly related to the afﬁnity of the
igands to sigma-1 receptors. Thus, in frontal cortical neurons,
igma-1 receptors appear to facilitate the desensitization of the
a2+ response to NMDA [33]. Attenuation of NMDA-induced cal-
ium responses by sigma ligands in frontal cortical neurons was
lso observed in a later study, and that study conﬁrmed that sigma
igands shifted the NMDA response from a sustained to a biphasic
r transient event [61].
In an interesting study on the sigma-1 receptor agonist
gmesine, the effect of intracerebroventricularly administeredn Research 221 (2011) 543–554
modulators of calcium inﬂux and mobilization was examined on
the reduction of immobilization time caused by igmesine in the
forced swimming test. Using chelators of extracellular and intra-
cellular calcium, L- andN-type voltage-dependent calcium channel
antagonists and agonists, evidence was obtained that the antide-
pressant effect of igmesine is dependent not only on rapid Ca2+
inﬂux (like that of classical antidepressants), but also on intracel-
lular Ca2+ mobilization [153].
Antagonists of voltage-dependent calcium channels such as
nimodipine impair the cognitive performance of rodents in various
learning tests. Such impairments could be attenuated by pre-
administration of the sigma-1 receptor agonists PRE084, and this
attenuation could be completely preventedby co-administration of
the sigma-1 receptor antagonist BMY14802. Thus, calcium ﬂuxes
are implied in memory processes and an impairment of calcium
inﬂux through voltage-dependent calcium channels can, at least
partially, be overcome by administration of a sigma-1 receptor
agonist [99]. Potentiation or attenuation of calcium signaling via
sigma-1 receptors (both Ca2+ entry at the plasma membrane level
via channels and Ca2+ mobilization from intracellular stores) may
explain why selective sigma-1 receptor agonists can modulate a
wide variety of neuronal responses, and be the key mechanism by
which sigma-1 receptors affect learning and memory [110].
9. Involvement of sigma-1 receptors in neuronal
differentiation and neuroplasticity
Sigma-1 receptors are expressed not only in neurons but also
in astrocytes and oligodendrocytes within the brain [35,37]. Over-
expression of sigma-1 receptors potentiates nerve growth factor
(NGF)-induced neurite outgrowth in PC-12 cells, and this effect can
be blocked by sigma-1 receptor antisense [144]. Sigma-1 recep-
tors are strongly upregulated in the corpus callosum of developing
brains, particularly in the phase of active myelination [37]. A high
expression of these binding sites is observed in oligodendrocytes
[127] and Schwann cells [128], suggesting involvement of the
sigma-1 receptor in myelination. Knockdown of these receptors
by siRNA results in complete inhibition of the differentiation and
myelination of oligodendrocyte progenitor cells [37] and preven-
tion of the formation of mature dendritic spines in hippocampal
primary neurons [149]. Eliprodil, a neuroprotective drug with
a high afﬁnity agonist action at sigma receptors, strongly pro-
motes myelination in neuron–oligodendrocyte cocultures. These
data suggest that upregulation of sigma-1 receptors is an important
prerequisite for neuronal differentiation, and that sigma-1 receptor
agonists like eloprodil may be of therapeutic interest in demyeli-
nating diseases such as multiple sclerosis [22].
Overexpression of sigma-1 receptors promotes lipid recon-
stitution in the plasma membrane and potentiates raft-residing
neurotrophic factors receptors and signal transduction (NGF, EGF,
BNDF) [38,145,146,160]. These neurotrophic factor signaling path-
ways may therefore be involved in the differentiation-promoting
effects of sigma-1 receptors. When PC-12 cells are treated with
NGF and verbenachalcone, a differentiation enhancer, the sigma-
1 receptor belongs to the 10 (out of 10,000) genes showing the
strongestupregulation [161]. Sinceaveryhighexpressionof sigma-
1 receptors has been noticed in the ventricular zone of young
rat brains, where active proliferation and differentiation of cells
occurs [37], sigma-1 receptors may not only play an important
role in neuroplasticity but may also be involved in neurogenesis.
An involvement of sigma-1 receptors in neurogenesis is sug-
gested by the observation that continuous administration of the
sigma-1 agonist SA4503 dose-dependently enhances the number
of bromodeoxyuridine-positive cells in the subgranular zone of
the adult rat hippocampus (by 48% at 3mg/kg/day and by 94%
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ndicating an increased cellular proliferation. Since SA4503 causes
arallel increases of hippocampal 5-HT neurotransmission and cell
roliferation, the neurotransmitter serotonin may play a central
ole in the proliferation process [67].
Not only sigma-1 receptor overexpression, but also drug-
nduced sigma-1 receptor activation results in potentiation of
GF-induced neurite outgrowth. Donepezil, a combined sigma-
receptor ligand and AChE inhibitor (IC50 values 14.6nM and
1.5nM, respectively [59]), potentiates NGF-induced neurite out-
rowth in PC-12 cells, and this effect of donepezil can be blocked
y the sigma-1 receptor antagonist NE-100 or the inositol 1,4,5-
riphosphate (IP3)-receptor antagonist xestospongin C [50], but
s not affected by cholinoceptor antagonists (mecamylamine,
copolamine) or cholinomimetic drugs (nicotine, carbachol) [125].
hysostigmine, an AChE inhibitor without sigma-1 receptor afﬁn-
ty, does not alter NGF-induced neurite outgrowth [50]. The SSRI
uvoxamine (but not the SSRIs sertraline or paroxetine) and the
igma-1 receptor agonists SA4503, PPBP andDHEA-sulfate likewise
otentiate neurite outgrowth in PC-12 cells in a concentration-
ependent manner, and the effect of these drugs can also be
locked by NE-100 or xestospongin C [120]. Since sertraline and
uvoxamine have similar afﬁnities to sigma-1 receptors [119] but
nly ﬂuvoxamine promotes outgrowth, these data may indicate
hat sertraline is a sigma-1 receptor antagonist and ﬂuvoxamine a
igma-1 receptor agonist [120]. Speciﬁc inhibitors of phospholipase
(PLC), phosphatidyl inositol 3-kinase (PI3K), p38 mitogen-
ctivated protein kinase (p38MAPK), c-Jun terminal kinase (JNK),
nd the Ras/Raf/mitogen-activated protein kinase signaling path-
ays block the potentiation of NGF-induced neurite outgrowth as
ell [120]. Apparently, both sigma-1 receptors and IP3 receptors
re involved in the potentiation of neurite outgrowth by the test
rugs, besides the PLC, PI3K, p38MAPK, JNK and the Ras/Raf/MAPk
ignaling pathways.
0. Conclusion
Because of the neuromodulatory role of sigma-1 receptors, lig-
nds for these binding sites can affect a large variety of cerebral
rocesses.Modiﬁcation of calcium transients (both by affecting cal-
ium release from intracellular stores and inﬂux of extracellular
alcium) and modulation of potassium channel activity via direct
rotein–protein interaction appear to be key processes under-
ying the action of sigma-1 receptor ligands. Probably via these
echanisms, several neurotransmitter systems are modulated,
articularly the cholinergic and glutamatergic (NMDA-receptor)
athways. The modulatory role of sigma-1 receptors explains why
igma-1 receptor ligands are usually devoid of an effect under
ontrol conditions buthave striking effectswhen thenormal home-
stasis of the organism has been disturbed, e.g. by disease or by a
harmacological challenge. Data from preclinical studies in a large
ariety of animal models suggests that sigma-1 receptor agonists
re promising compounds for the treatment of cognitive dysfunc-
ion.
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